BRPI0415562B8 - método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio - Google Patents

método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio

Info

Publication number
BRPI0415562B8
BRPI0415562B8 BRPI0415562A BRPI0415562A BRPI0415562B8 BR PI0415562 B8 BRPI0415562 B8 BR PI0415562B8 BR PI0415562 A BRPI0415562 A BR PI0415562A BR PI0415562 A BRPI0415562 A BR PI0415562A BR PI0415562 B8 BRPI0415562 B8 BR PI0415562B8
Authority
BR
Brazil
Prior art keywords
carcinoma
lap
prognostic
immunoassay kit
patient
Prior art date
Application number
BRPI0415562A
Other languages
English (en)
Inventor
Mizutani Shigehiko
Original Assignee
Suntory Holdings Ltd
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd, Suntory Ltd filed Critical Suntory Holdings Ltd
Publication of BRPI0415562A publication Critical patent/BRPI0415562A/pt
Publication of BRPI0415562B1 publication Critical patent/BRPI0415562B1/pt
Publication of BRPI0415562B8 publication Critical patent/BRPI0415562B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma. a presente invenção proporciona um reagente para avaliação prognóstica de pacientes com carcinoma, compreendendo um anticorpo anti-p-lap como um ingrediente ativo. também, a presente invenção proporciona um método para a determinação de p-lap que é um fator prognóstico em pacientes com carcinoma compreendendo (a) uma etapa de contatar tecidos de carcinoma obtidos de pacientes com carcinoma por operação cirúrgica com um anticorpo anti-p-lap e (b) uma etapa de medir a intensidade da reação específica de antígeno-anticorpo entre p-lap presente nos tecidos de carcinoma e o anticorpo anti-p-lap.
BRPI0415562A 2003-10-21 2004-09-15 método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio BRPI0415562B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003360638 2003-10-21
PCT/JP2004/013883 WO2005038462A1 (en) 2003-10-21 2004-09-15 Method for prognostic evaluation of carcinoma using anti-p-lap antibody

Publications (3)

Publication Number Publication Date
BRPI0415562A BRPI0415562A (pt) 2007-01-02
BRPI0415562B1 BRPI0415562B1 (pt) 2020-02-04
BRPI0415562B8 true BRPI0415562B8 (pt) 2021-07-27

Family

ID=34463417

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415562A BRPI0415562B8 (pt) 2003-10-21 2004-09-15 método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio

Country Status (5)

Country Link
US (1) US7666605B2 (pt)
JP (1) JP4635004B2 (pt)
BR (1) BRPI0415562B8 (pt)
CA (1) CA2542823C (pt)
WO (1) WO2005038462A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984546A4 (en) * 2006-01-24 2009-09-23 Univ British Columbia POLYMORPHISMS OF THE VASOPRESSIN SIGNALING PATH AS INDICATORS OF THE EVOLUTION OF STATUS OF SUBJECTS IN SUBJECTS SERIOUSLY REACHED
US7689554B2 (en) * 2006-02-28 2010-03-30 Yahoo! Inc. System and method for identifying related queries for languages with multiple writing systems
FR2933411B1 (fr) 2008-07-04 2013-04-19 Univ Joseph Fourier Utilisation de la proteine irap pour la mise en oeuvre de methodes de diagnostic et de pronostique
FR2945808B1 (fr) * 2009-05-20 2013-12-27 Univ Joseph Fourier Peptides marques et leur utilisation pour le dosage d'irap circulant
JP7313005B2 (ja) * 2019-06-25 2023-07-24 医療法人三栄会 がんのバイオマーカーおよびがんの発症を判定する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4129704B2 (ja) * 1998-09-22 2008-08-06 ニプロ株式会社 ロイシンアミノペプチダーゼ活性測定用試薬

Also Published As

Publication number Publication date
CA2542823C (en) 2015-05-26
US7666605B2 (en) 2010-02-23
JP4635004B2 (ja) 2011-02-16
JP2007509313A (ja) 2007-04-12
BRPI0415562B1 (pt) 2020-02-04
BRPI0415562A (pt) 2007-01-02
WO2005038462A1 (en) 2005-04-28
CA2542823A1 (en) 2005-04-28
US20070020705A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
CY1120296T1 (el) ΔΙΑΛΥΤΟΣ ΥΠΟΔΟΧΕΑΣ ΕΝΕΡΓΟΠΟΙΗΤΗ ΤΟΥ ΠΛΑΣΜΙΝΟΓΟΝΟΥ ΤΥΠΟΥ ΟΥΡΟΚΙΝΑΣΗΣ (suPAR) ΩΣ ΔΙΑΓΝΩΣΤΙΚΟΣ ΔΕΙΚΤΗΣ ΓΙΑ ΧΑΜΗΛΟΥ ΒΑΘΜΟΥ ΦΛΕΓΜΟΝΗ
BRPI0516674A (pt) método de análise de mal de alzheimer e reagente de diagnóstico
DK1889059T3 (da) Fremgangsmåde til forbedret immunoassay
DE602005015894D1 (de) Diagnostische testvorrichtung
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
BR112017021305A2 (pt) dispositivo de teste de fluxo lateral, e, método e kit para detecção quantitativa de um analito em uma amostra de saliva
EP2319941A3 (en) Method and apparatus for correlating levels of biomarker products with disease
WO2007002579A3 (en) Assay cartridges and methods for point of care instruments
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
BR112013000869A2 (pt) método para diagnóstico de câncer de próstata (pca) com uma sensibilidade desejada em um sujeito; método para monitorar a progressão do câncer de próstata (pca) em um sujeito; método para avaliar se um sujeito tem que ser submetido a uma biópsia de próstata; kit compreendendo um primeiro componente e, opcionalmente, um segundo componente e uso de um kit
SG171691A1 (en) Biomarkers for diagnosing multiple sclerosis, and methods thereof
BRPI0509978A (pt) uso de padrão proteÈmico de plasma para diagnóstico, classificação, previsão de resposta à terapia e comportamento clìnico, estratificação de terapia, e monitoramento de doença em malignidades hematológicas
EP1836956A3 (en) Activity-induced energy expenditure estimating instrument
WO2008132464A3 (en) Mek5 and related proteins as biomarkers of neurodegenerative diseases
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
Faix et al. Progress in standardizing and harmonizing thyroid function tests
BRPI0512948A (pt) biomarcadores de mal de alzheimer
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
ATE406579T1 (de) Verfahren zur diagnose von tumoren
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
BRPI0415562B8 (pt) método in vitro para avaliação prognóstica de carcinoma de ovário em um paciente, e, kit de imunoensaio
ATE369564T1 (de) Differenzielles immunoassay für myoglobin
DE602005010548D1 (de) Verbessertes verfahren zur diagnose des akuten koronarsyndroms

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SUNTORY HOLDINGS LIMITED (JP)

Free format text: TRANSFERIDO DE: SUNTORY LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO